Cognitive and academic outcomes in children with myelin oligodendrocyte glycoprotein antibody-associated disease.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
revised:
22
07
2024
received:
19
04
2023
accepted:
29
07
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
aheadofprint
Résumé
To describe the impact of paediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) on academic and cognitive outcomes. This was an observational, retrospective, and descriptive single-centre study, carried out on a paediatric case series of children with MOGAD. A total of 51 patients were included (22 females); their median age was 8 years and the median follow-up duration was 31.1 months (interquartile range 23.5). The most frequent clinical presentation was acute disseminated encephalomyelitis (54.9%), followed by optic neuritis (35.5%). At the last follow-up, regardless of the clinical phenotype at disease onset, 39.5% of patients with MOGAD received academic and educational interventions (p < 0.05 compared to before disease onset), including academic accommodations (p < 0.05) or the need for a learning support assistant (p < 0.05). Ten patients were evaluated with the Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V). The overall IQ was calculated for six patients (mean = 92); two of these patients had an IQ lower than 85. No difference was found regarding prenatal and neonatal neurodevelopmental characteristics between this cohort and the general population. MOGAD was associated with a need for academic support; lower scores were found on the WISC-V. Patients with MOGAD should receive cognitive and academic assessments to inform educational planning and support academic success.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
Références
de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti‐MOG‐associated acquired demyelinating syndromes in children and adults. Mult Scler Houndmills Basingstoke Engl. 2020 Jun;26(7):806–14.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody‐associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268–82.
Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non‐MS course in children. Neurol ‐ Neuroimmunol Neuroinflammation. 2015 Apr;2(2):e81.
Hennes EM, Baumann M, Schanda K, Anlar B, Bajer‐Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017 Aug 29;89(9):900–8.
Bruijstens AL, Lechner C, Flet‐Berliac L, Deiva K, Neuteboom RF, Hemingway C, et al. E.U. paediatric MOG consortium consensus: Part 1 ‐ Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody‐associated disorders. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2020 Nov;29:2–13.
Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O, et al. Myelin oligodendrocyte glycoprotein and aquaporin‐4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol. 2018 Sep;60(9):958–62.
Fernandez‐Carbonell C, Vargas‐Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler Houndmills Basingstoke Engl. 2016 Feb;22(2):174–84.
Rossor T, Benetou C, Wright S, Duignan S, Lascelles K, Robinson R, et al. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler J. 2020 Mar;26(3):333–42.
Waters P, Fadda G, Woodhall M, O'Mahony J, Brown RA, Castro DA, et al. Serial Anti‐Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020 Jan 1;77(1):82–93.
Konuskan B, Yildirim M, Gocmen R, Okur TD, Polat I, Kilic H, et al. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody‐related disorders. Mult Scler Relat Disord. 2018 Nov;26:1–7.
Mao L, Yang L, Kessi M, He F, Zhang C, Wu L, et al. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes. Front Neurol. 2019;10:868.
Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, et al. E.U. paediatric MOG consortium consensus: Part 4 ‐ Outcome of paediatric myelin oligodendrocyte glycoprotein antibody‐associated disorders. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2020 Nov;29:32–40.
Fabri TL, O'Mahony J, Fadda G, Gur RE, Gur RC, Yeh EA, et al. Cognitive function in pediatric‐onset relapsing myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD). Mult Scler Relat Disord. 2022 Mar;59:103689.
Armangue T, Olivé‐Cirera G, Martínez‐Hernandez E, Sepulveda M, Ruiz‐Garcia R, Muñoz‐Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020 Mar;19(3):234–46.
Wong YYM, Hacohen Y, Armangue T, Wassmer E, Verhelst H, Hemingway C, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol. 2018 May;25(5):782–6.
Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease. JAMA Neurol. 2018 Apr 1;75(4):478–87.
Deiva K, Cobo‐Calvo A, Maurey H, De Chalus A, Yazbeck E, Husson B, et al. Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody‐associated acute demyelinating syndromes. Dev Med Child Neurol. 2020 Sep;62(9):1075–81.
Zhou J, Lu X, Zhang Y, Ji T, Jin Y, Xu M, et al. Follow‐up study on Chinese children with relapsing MOG‐IgG‐associated central nervous system demyelination. Mult Scler Relat Disord. 2019 Feb;28:4–10.
Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune‐mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J. 2013 Sep;19(10):1261–7.
Cobo‐Calvo Á, d'Indy H, Ruiz A, Collongues N, Kremer L, Durand‐Dubief F, et al. Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross‐sectional study. Neurol Neuroimmunol Neuroinflammation. 2020 Mar;7(2):e649.
Weiss LG, Saklofske DH, Holdnack JA, Prifitera A. WISC‐V. In: WISC‐V Assessment and Interpretation [Internet]. Elsevier; 2016 [cited 2023 Sep 16]. p. 3–23. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780124046979000017
Baumann M, Hennes EM, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Mult Scler Houndmills Basingstoke Engl. 2016 Dec;22(14):1821–9.
Welcome on the site AUDIPOG [Internet]. [cited 2022 Sep 14]. Available from: https://www.audipog.net/
Storm Van's Gravesande K, Calabrese P, Blaschek A, Rostásy K, Huppke P, Rothe L, et al. The Multiple Sclerosis Inventory of Cognition for Adolescents (MUSICADO): A brief screening instrument to assess cognitive dysfunction, fatigue and loss of health‐related quality of life in pediatric‐onset multiple sclerosis. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2019 Nov;23(6):792–800.